European equities traded in the US as American depositary receipts were moving lower late Friday morning, declining 0.85% to 1,302.64 on the S&P Europe Select ADR Index, which is down about 2.8% for ...

Zai Lab and argenx have announced receipt of approval from the National Medical Products Administration (NMPA) of China for ...

Wolfe Research upgraded Argenx (ARGX) to Outperform from Peer Perform with a $697 price target Now through 2025, there will be few exciting ...

Argenx Se (ARGX) has released an update. Argenx SE and Zai Lab Limited have announced that their drug VYVGART Hytrulo has received approval ...

Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA ...

argenx SE (NASDAQ:ARGX – Free Report) – Investment analysts at Wedbush increased their Q1 2025 earnings per share (EPS) ...

(NASDAQ:ARGX – Get Free Report) was downgraded by investment analysts at Baird R W from a “strong-buy” rating to a “hold” ...

Argenx (NASDAQ:ARGX) announces that it has updated the number of ADSs in its U.S. public offering to 3.5M ADSs yielding $150M. Each of the ADSs represents one ordinary... Investing.com – U.S ...

A live webcast of the Guggenheim fireside chat may be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & Nasdaq: ARGX) today announced that China’s National Medical Products Administrat ...

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced ...

Amsterdam, the Netherlands— (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the ...